The US FDA has approved four COVID vaccines targeting the XFG variant for the 2026-2027 season, developed by Moderna, Pfizer and BioNTech, Novavax, and Sanofi. While the vaccines are available for high-risk individuals, the CDC’s lack of guidance leads to… Read More »FDA approves four new COVID vaccines for the 2026-27 season
Professor Dorit Rubinstein Reiss discusses the challenges and dangers of splitting the MMR vaccine into separate doses for measles, mumps, and rubella. The process is complex, costly, and unlikely to increase safety. Reiss argues it could lead to lower vaccination… Read More »Splitting the MMR vaccine into its three components will be difficult
Moderna’s mRNA-1010 flu vaccine has received FDA approval for adults aged 50 and older, marking it as the first mRNA-based flu vaccine in the U.S. It demonstrates 26.6% higher effectiveness than standard vaccines. While adverse events were more frequent, most… Read More »FDA approves first mRNA flu vaccine for people over 50
On February 10, 2026, the FDA denied Moderna’s biologics license application for its mRNA flu vaccine, citing insufficient trial data. After a meeting with Moderna on February 18, the FDA agreed to review a revised application, aiming for potential approval… Read More »FDA reverses itself and will review Moderna mRNA flu vaccine
On February 10, 2026, the FDA denied Moderna’s request for a biologics license application for its mRNA flu vaccine, mRNA-1010, citing inadequate trials. This refusal may hinder vaccine innovation and marketability in the U.S., reflecting concerns over anti-vaccine influences, particularly… Read More »FDA refused to review the Moderna mRNA flu vaccine application
Rumors regarding HHS Secretary RFK Jr’s intent to eliminate COVID vaccines have surfaced, but the FDA approved new versions for Fall 2025. While vaccines are available for all individuals 65 and older, those under 64 must have high-risk conditions to… Read More »FDA approves Fall 2025 COVID vaccines with restrictions
The article discusses the resurgence of anti-vaccine claims regarding thimerosal, particularly by Robert F. Kennedy Jr. It emphasizes that thimerosal is not linked to autism and is primarily present in multi-dose flu vaccines. Both the CDC and FDA confirm its… Read More »CDC vaccine advisors to discuss thimerosal in flu vaccines
The CDC plans to study potential links between vaccines and autism, despite extensive evidence refuting such claims. Historically, Andrew Wakefield’s 1998 fraudulent study sparked the controversy. Genetic and environmental factors contribute to autism, while vaccines have consistently been shown to… Read More »CDC study to find link between vaccines and autism — REVISED
Robert F Kennedy Jr and his HHS canceled a crucial VRBPAC meeting that evaluates flu vaccine strains for the 2025-26 season. This cancellation poses a significant risk to vaccine development, limiting expert discussions on flu strains. VRBPAC’s role is essential… Read More »Flu vaccine development process and how RFK Jr is damaging it
The article speculates on the potential negative impact of Robert F. Kennedy Jr. as Secretary of Health and Human Services, particularly regarding vaccinations and public health initiatives. It highlights his anti-vaccine stance and suggests he may manipulate agencies like the… Read More »What could RFK Jr do as HHS Secretary?